Rapid and accurate identification of poliovirus strains used for vaccine production

Journal of Virological Methods

Volumn 189, Issue 1, 2013, Pages 189-195

  Nijst, Olaf E M ^a   Mouthaan, Justin J ^a   Mekkes, Dirk R ^b   Jusic, Edin ^a   van der Avoort, Harrie G A M ^a   Metz, Bernard ^a  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^b Bilthoven Biologicals   (Netherlands)

Author keywords

Mahoney; MEF 1; Poliovirus; Real time PCR; Sabin; Saukett; Vaccine; Vaccine related polioviruses

Indexed keywords

POLIOMYELITIS VACCINE; VIRUS RNA;

ANALYTICAL PARAMETERS; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HIGH THROUGHPUT SEQUENCING; HYBRIDIZATION; MOLECULAR PROBE; NONHUMAN; POLIOMYELITIS VIRUS; POLIOMYELITIS VIRUS MAHONEY; POLIOMYELITIS VIRUS MEF 1; POLIOMYELITIS VIRUS SABIN TYPE 1; POLIOMYELITIS VIRUS SABIN TYPE 2; POLIOMYELITIS VIRUS SABIN TYPE 3; POLIOMYELITIS VIRUS SUAKETT H; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; VACCINE PRODUCTION; VIRUS IDENTIFICATION; VIRUS LOAD; VIRUS STRAIN;

ANTIBODIES, VIRAL; CELL LINE; HUMANS; POLIOMYELITIS; POLIOVIRUS; POLIOVIRUS VACCINE, INACTIVATED; POLIOVIRUS VACCINE, ORAL; POLYMERASE CHAIN REACTION; RNA, VIRAL;

POLIOVIRUS;

EID: 84875495712     PISSN: 01660934     EISSN: 18790984     Source Type: Journal    
DOI: 10.1016/j.jviromet.2013.01.026     Document Type: Article

References (28)

1. Boot H.J., Schepp R.M., van Nunen F.J., Kimman T.G. Rapid RT-PCR amplification of full-length poliovirus genomes allows rapid discrimination between wild-type and recombinant vaccine-derived polioviruses. J. Virol. Methods 2004, 116:35-43.
2. Chumakov K.M., Norwood L.P., Parker M.L., Dragunsky E.M., Ran Y.X., Levenbook I.S. RNA sequence variants in live poliovirus vaccine and their relation to neurovirulence. J. Virol. 1992, 66:966-970.
3. Crawford N.W., Buttery J.P. Poliomyelitis eradication: another step forward. Lancet 2010, 376:1624-1625.
4. Dragunsky E.M., Ivanov A.P., Wells V.R., Ivshina A.V., Rezapkin G.V., Abe S., Potapova S.G., Enterline J.C., Hashizume S., Chumakov K.M. Evaluation of immunogenicity and protective properties of inactivated poliovirus vaccines: a new surrogate method for predicting vaccine efficacy. J. Infect. Dis. 2004, 190:1404-1412.
5. Dutta A. Epidemiology of poliomyelitis - options and update. Vaccine 2008, 26:5767-5773.
6. Furione M., Guillot S., Otelea D., Balanant J., Candrea A., Crainic R. Polioviruses with natural recombinant genomes isolated from vaccine-associated paralytic poliomyelitis. Virology 1993, 196:199-208.
7. Heymann D.L., Sutter R.W., Aylward R.B. A global call for new polio vaccines. Nature 2005, 434:699-700.
8. Heymann D.L., Sutter R.W., Aylward R.B. A vision of a world without polio: the OPV cessation strategy. Biologicals 2006, 34:75-79.
9. Kew O.M., Sutter R.W., de Gourville E.M., Dowdle W.R., Pallansch M.A. Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Annu. Rev. Microbiol. 2005, 59:587-635.
10. Kilpatrick D.R., Ching K., Iber J., Campagnoli R., Freeman C.J., Mishrik N., Liu H.M., Pallansch M.A., Kew O.M. Multiplex PCR method for identifying recombinant vaccine-related polioviruses. J. Clin. Microbiol. 2004, 42:4313-4315.
11. Kilpatrick D.R., Nottay B., Yang C.F., Yang S.J., Da Silva E., Penaranda S., Pallansch M., Kew O. Serotype-specific identification of polioviruses by PCR using primers containing mixed-base or deoxyinosine residues at positions of codon degeneracy. J. Clin. Microbiol. 1998, 36:352-357.
12. Kilpatrick D.R., Nottay B., Yang C.F., Yang S.J., Mulders M.N., Holloway B.P., Pallansch M.A., Kew O.M. Group-specific identification of polioviruses by PCR using primers containing mixed-base or deoxyinosine residue at positions of codon degeneracy. J. Clin. Microbiol. 1996, 34:2990-2996.
13. Kilpatrick D.R., Yang C.F., Ching K., Vincent A., Iber J., Campagnoli R., Mandelbaum M., De L., Yang S.J., Nix A., Kew O.M. Rapid group-, serotype-, and vaccine strain-specific identification of poliovirus isolates by real-time reverse transcription-PCR using degenerate primers and probes containing deoxyinosine residues. J. Clin. Microbiol. 2009, 47:1939-1941.
14. La Monica N., Meriam C., Racaniello V.R. Mapping of sequences required for mouse neurovirulence of poliovirus type 2 Lansing. J. Virol. 1986, 57:515-525.
15. Martin J., Minor P.D. Characterization of CHAT and Cox type 1 live-attenuated poliovirus vaccine strains. J. Virol. 2002, 76:5339-5349.
16. Neverov A., Chumakov K. Massively parallel sequencing for monitoring genetic consistency and quality control of live viral vaccines. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:20063-20068.
17. Otelea D., Guillot S., Furione M., Combiescu A.A., Balanant J., Candrea A., Crainic R. Genomic modifications in naturally occurring neurovirulent revertants of Sabin 1 polioviruses. Dev. Biol. Stand. 1993, 78:33-38.
18. Sambrook J., Fritsch E.F., Maniatis T. Molecular Cloning 1989, Cold Spring Harbor Laboratory Press, New York. second ed.
19. Stanway G., Hughes P.J., Mountford R.C., Reeve P., Minor P.D., Schild G.C., Almond J.W. Comparison of the complete nucleotide sequences of the genomes of the neurovirulent poliovirus P3/Leon/37 and its attenuated Sabin vaccine derivative P3/Leon 12a1b. Proc. Natl. Acad. Sci. U. S. A. 1984, 81:1539-1543.
20. Sutter R.W., John T.J., Jain H., Agarkhedkar S., Ramanan P.V., Verma H., Deshpande J., Singh A.P., Sreevatsava M., Malankar P., Burton A., Chatterjee A., Jafari H., Aylward R.B. Immunogenicity of bivalent types 1 and 3 oral poliovirus vaccine: a randomised, double-blind, controlled trial. Lancet 2010, 376:1682-1688.
21. van der Avoort H.G., Hull B.P., Hovi T., Pallansch M.A., Kew O.M., Crainic R., Wood D.J., Mulders M.N., van Loon A.M. Comparative study of five methods for intratypic differentiation of polioviruses. J. Clin. Microbiol. 1995, 33:2562-2566.
22. van Wezel A.L., Hazendonk A.G. Intratypic serodifferentiation of poliomyelitis virus strains by strain-specific antisera. Intervirology 1979, 11:2-8.
23. van Wezel A.L., van Herwaarden J.A., van de Heuvel-de Rijk E.W. Large-scale concentration and purification of virus suspension from microcarrier culture for the preparation of inactivated virus vaccines. Dev. Biol. Stand. 1979, 42:65-69.
24. van Wezel A.L., van Steenis G., Hannik C.A., Cohen H. New approach to the production of concentrated and purified inactivated polio and rabies tissue culture vaccines. Dev. Biol. Stand. 1978, 41:159-168.
25. Westdijk J., Brugmans D., Martin J., van't Oever A., Bakker W.A., Levels L., Kersten G. Characterization and standardization of Sabin based inactivated polio vaccine: proposal for a new antigen unit for inactivated polio vaccines. Vaccine 2011, 29:3390-3397.
26. WHO, 2003. Global Polio Eradication Initiative Strategic Plan 2004-2008, Geneva.
27. WHO, 2004. Polio Laboratory Manual, Geneva.
28. WHO Global Polio Case Count 2012, Available from:, (21.08.12). http://www.polioeradication.org/Dataandmonitoring/Poliothisweek.aspx.